[CAS NO. 1425944-33-7] CYD-4-61
PRODUCTS SPECIFICATIONS [1425944-33-7]
DESCRIPTION [1425944-33-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 359.38 |
| Molecular Formula | C21H17N3O3 |
| SMILES | NCCOC1=NC=CC=C1/C=C2C3=C(C4=C/2C=CC=C4)C=CC([N+]([O-])=O)=C3 |
Summary
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis [1] .
IC50 & Target
|
Bax |
In Vitro
CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC
50
s of 0.07 µM against triple-negative breast cancer MDA-MB-231 and 0.06 µM against ER-positive breast cancer MCF-7 cell lines, respectively
[1]
.
CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells
[1]
.
CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells
[1]
.
CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | MCF-10A, T47D, MCF-7, MDA-MB-231, and MDA-MB-468 cells |
| Concentration: | 0.1, 1, and 10 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation and viability. |
Western Blot Analysis [1]
| Cell Line: | MCF-7 and MDA-MB-231 cells |
| Concentration: | 5 μM |
| Incubation Time: | 0, 6, 12, 24, and 48 hours |
| Result: | Dose-dependently led to the upregulation of cleaved PARP-1, cleaved caspase 3, and downregulation of cyclin D1. |
In Vivo
CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Triple-negative breast cancer MDA-MB-231 xenograft model in mice [1] |
| Dosage: | 2.5 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 7 consecutive days |
| Result: | Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.